Cogent Q3 net loss $70.6M; PEAK trial enrolls 413 patients, top-line data in 2025

Cogent Biosciences, Inc.

2024-Q3 EPS reported -$1.85

Net loss $70.6M in Q3 2024 vs $55.4M in Q3 2023; cash $345.5M sufficient into late 2026.
Phase 3 PEAK GIST trial completed enrollment (413 patients); IDMC recommended continuation after futility analysis.
Top-line results expected from SUMMIT (2H 2025), APEX (mid-2025), PEAK (end of 2025).
Phase 1 trial initiated for CGT-4859 FGFR2 inhibitor; preclinical data for KRAS and PI3K inhibitors presented.
Inducement grants of options to purchase 132,350 shares to three new employees.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.